English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA new study from researchers at Wake Forest University School of Medicine is shedding light on how scientific evidence and the uncertainty surrounding three unproven therapeutics were portrayed by the U.S. news media during the early days of the COVID-19 pandemic.
Tag: Convalescent Plasma
The AABB releases clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma
The Association for the Advancement of Blood and Biotherapies (AABB) has released clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma (CCP) in hospital and outpatient settings. Based on two living systematic reviews of randomized controlled trials (RCTs), the guidelines provide five specific recommendations for treating patients with COVID-19 and suggest that CCP is most effective when transfused with high neutralizing titers to infected patients early after symptom onset. The guidelines are published in Annals of Internal Medicine.
Treating newly infected COVID-19 patients with plasma from COVID survivors demonstrates no significant benefit, study finds
A NIH study co-led and designed by Michigan Medicine researchers found that using convalescent plasma to treat newly infected #COVID-19 patients demonstrated no significant benefit. The trial was stopped in February 2021 due to lack of efficacy based on planned interim analysis
Treating newly infected COVID-19 patients with plasma from COVID survivors demonstrates no significant benefit, study finds
A NIH study co-led and designed by Michigan Medicine researchers found that using convalescent plasma to treat newly infected #COVID-19 patients demonstrated no significant benefit. The trial was stopped in February 2021 due to lack of efficacy based on planned interim analysis
Blood cancer patients with COVID-19 fare better with convalescent plasma
A large, retrospective, multicenter study involving Washington University School of Medicine in St. Louis indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients hospitalized with the virus. The therapy involves transfusing plasma — the pale yellow liquid in blood that is rich in antibodies — from people who have recovered from COVID-19 into patients who have leukemia, lymphoma or other blood cancers and are hospitalized with the viral infection.
Drop in Convalescent Plasma Use at U.S. Hospitals Linked to Higher COVID-19 Mortality Rate
A new study from researchers at Johns Hopkins Bloomberg School of Public Health and colleagues suggests a slowdown in the use of convalescent plasma to treat hospitalized COVID-19 patients led to a higher COVID-19 mortality during a critical period during this past winter’s surge.
Hackensack Meridian Health Publication: COVID-19 Convalescent Plasma with Greater Antibody Levels is Safe and Shows Promise
The treatment was safe, transferred the survivors’ antibodies, and did not prevent the recipients from making their own antibodies, according to the results published recently in the journal JCI Insights.
Monoclonal Antibody “Cocktail” Blocks COVID-19 Variants: Study
A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center (VUMC) to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published in the journal Nature Medicine.
Convalescent Plasma Improved Survival in COVID-19 Patients with Blood Cancers
Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).
Hackensack Meridian Health Awarded $5.5 Million by Department of Defense to Continue Convalescent Plasma Work for COVID-19
The goal of this outpatient work is to treat infected patients in the first 96 hours of symptoms with the antibodies found in plasma collected from COVID-19 survivors – with the aim to prevent hospitalization.
Story Tips from Johns Hopkins Experts on COVID-19
Vaccines take time to work. After getting a COVID-19 vaccine, it takes a while for the immune system to fully respond and provide protection from the virus. For the Moderna and Pfizer COVID-19 vaccines, it takes up to two weeks after the second shot to become appropriately protected.
Hackensack Meridian Health Convalescent Plasma Work for COVID-19 Treatments Enters Next Phase of Study
The new Phase 2 study is for infusing this potentially valuable serum into patients with early-stage COVID-19 infection who have at least one major risk factor for serious disease, in an outpatient setting. The goal is to treat the patients in the first 96 hours – with the aim to prevent hospitalization entirely.
Small Study Shows Convalescent Plasma is Safe to Use in Pediatric Patients with COVID-19
Early findings from researchers at Children’s Hospital of Philadelphia (CHOP) show that convalescent plasma appears to be a safe and possibly effective treatment for children with life-threatening cases of COVID-19. The results were published online Friday by the journal Pediatric Blood and Cancer.
ATS Statement on Latest COVID-19 Policy Actions: Convalescent Plasma and Testing of Asymptomatic Patients
The American Thoracic Society is alarmed by two federal agency policy actions that may significantly impact our nation’s COVID-19 response. This week, the FDA issued an emergency use authorization (EUA) for the use of convalescent plasma to treat COVID-19 disease. This action was taken despite a lack of adequate evidence demonstrating a clear benefit for most patients. As pulmonary and critical care clinicians and researchers who treat individuals with COVID-19, we are concerned that an EUA for convalescent plasma has the potential to put patients at risk.
VUMC Awarded $34 Million to Lead Nationwide Convalescent Plasma Study
Vanderbilt University Medical Center (VUMC) has been awarded a one-year, $34-million grant by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, to conduct a nationwide study of “convalescent plasma” as a treatment for COVID-19.
Dr. Luis Ostrosky available to talk about first Texas randomized study on convalescent plasma
Dr. Luis Ostrosky, professor of infectious disease at McGovern Medical School at UTHealth, co-investigator of first Texas randomized trial for convalescent therapy for COVID-19, is available to discuss latest data and FDA’s hold on the emergency authorization of blood plasma…
Convalescent Plasma Associated with Reduced COVID-19 Mortality in 35,000-Plus Hospitalized Patients
Mayo Clinic and collaborators have published a preprint that identifies two main signals of efficacy that can inform future clinical trials on plasma therapy on COVID-19 patients. The data are extracted from the Mayo-led national Expanded Access Program (EAP) for convalescent plasma for the treatment of hospitalized patients with COVID-19.
Baylor Scott & White Research Institute Expands Efforts in the Fight Against COVID-19
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
Team is first in Texas to investigate convalescent plasma for prevention of COVID-19 onset and progression
A research team is the first in Texas to investigate whether plasma from COVID-19 survivors can be used in outpatient settings to prevent the onset and progression of the virus in two new clinical trials at UTHealth.
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense
– ImmunoTek to extend operating license and provide training to Mount Sinai to establish onsite plasma collection to support production of COVID-HIG
Mayo Finds Convalescent Plasma Safe for Diverse Patients with COVID-19
Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findings — from the U.S. Food and Drug Administration’s Expanded Access Program for COVID-19 — are reported in Mayo Clinic Proceedings.
Mount Sinai seeks EUA from Food and Drug Administration for potential quantitative serologic test for COVID-19
If authorized for quantitative use, the assay could be used to provide a numeric result for the concentration of neutralizing anti-COVID-19 antibodies in plasma.
Cancer Researchers Have a Head Start in Fight Against COVID-19
Researchers at Roswell Park Comprehensive Cancer Center have been actively engaged in the effort to develop treatments or other control strategies that can help communities worldwide to address the impacts of the COVID-19 pandemic.
Convalescent Plasma Is A Potentially Effective Treatment Option for Patients Hospitalized With COVID 19, According to Early Data
Patients hospitalized with COVID-19 who received convalescent plasma demonstrated improved survival and were more likely than matched control patients to remain the same or have improvements in their supplemental oxygen requirements, according to a study conducted by researchers at the Icahn School of Medicine at Mount Sinai and published today on pre-print server medRxiv.
Mayo Clinic receives $26 million from BARDA for COVID-19 convalescent plasma expanded access program
Mayo Clinic was awarded a $26 million contract today from the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The financial support is for the Expanded Access Program (EAP) for convalescent plasma to fight COVID-19. Announced by the U.S. Food and Drug Administration on April 3, the national program, which is led by Mayo Clinic researcher Michael Joyner, M.D., coordinates a national online physician/patient registry (uscovidplasma.org) that speeds access and increases availability of experimental convalescent plasma for hospitalized patients in need.
Clinical Trial Begins to See if Convalescent Plasma Can Treat COVID-1
Montefiore Health System, Albert Einstein College of Medicine and NYU Langone have launched a new clinical trial to study if convalescent plasma—taken from people who have recovered from COVID-19—is effective in treating the disease.
Baylor Scott & White Research Institute Exploring Potential Prevention Options, Therapies for COVID-19
Baylor Scott & White Research Institute, the research arm of Baylor Scott & White Health, is bringing clinical trials online at an unprecedented pace in response to COVID-19. A COVID-19 therapeutic task force of more than 20 multidisciplinary researchers positioned across the state of Texas has been putting their expertise in infectious disease, cardiology, immunology, molecular biology, and other specialties together to explore research opportunities for experimental prevention and treatment options and to develop investigator-initiated studies.
Rutgers, University Hospital Lead Way in Treating COVID-19 with Convalescent Plasma from Recovered Patients
Rutgers physicians and University Hospital are leading the way in using blood plasma from patients who recovered from COVID-19 to treat new patients who are severely ill with COVID-19 infections.
DARPA-funded microchip technology optimizes convalescent plasma therapy for COVID-19 patients
A consortium of California scientists from government, academia and business today published an initial manuscript describing a novel approach to prepare convalescent plasma for COVID-19 patients in BioRxiv.